Pharmaceutical Technology26 天
Dalnicastobart by Lyvgen Biopharma for Oral Cavity (Mouth) Cancer: Likelihood of Approval
oral cavity cancer, oropharyngeal cancer, laryngeal cancer and hypopharyngeal cancer. It is a humanized monoclonal antibody that acts by targeting CD40. It is administered through intravenous and oral ...
Pharmaceutical Technology26 天
Dazostinag sodium by Takeda Pharmaceutical for Paranasal Sinus And Nasal Cavity Cancer ...
Dazostinag sodium is under clinical development by Takeda Pharmaceutical and currently in Phase II for Paranasal Sinus And Nasal Cavity Cancer. According to GlobalData, Phase II drugs for Paranasal ...